

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Vertex Pharmaceuticals (deutivacaftor, tezacaftor, vanzacaftor) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Asthma and Lung UK • CF Voices • Cystic Fibrosis Care • Cystic Fibrosis Trust • Gene People • Genetic Alliance • NARA – The Breathing Charity • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association for Respiratory Technology and Physiology • Association of Chartered Physiotherapists in Cystic Fibrosis • Association of Genetic Nurses and Counsellors • Association of Respiratory Nurse Specialists • British Dietetic Association • British Geriatrics Society • British Inherited Metabolic Disease Group • British Paediatric Respiratory Society • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society of Medical Genetics • British Thoracic Society • Chartered Society of Physiotherapy • Cystic Fibrosis Nursing Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Vertex Pharmaceuticals (elexacaftor, lumacaftor and ivacaftor) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Association for Lung Research • Cochrane Airways Group • Cochrane Cystic Fibrosis and Genetic Disorders Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UK Cystic Fibrosis Gene Therapy Consortium <p><u>Associated Public Health groups</u></p>

Provisional stakeholder list for the evaluation of vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

Issue date: September 2024

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • ENT UK • Interstitial Lung Diseases Interdisciplinary Network (ILD-IN) • National Heart and Lung Institute • Neonatal and Paediatric Pharmacists Group (NPPG) • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Cystic Fibrosis Medical Association • UK Cystic Fibrosis Pharmacy Group • UK Psychosocial Professionals in Cystic Fibrosis Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

Issue date: September 2024

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.